Clinical features and outcomes of breakthrough vitreous hemorrhage secondary to polypoidal choroidal vasculopathy.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
09
2022
accepted:
14
12
2022
entrez:
30
12
2022
pubmed:
31
12
2022
medline:
4
1
2023
Statut:
epublish
Résumé
Polypoidal choroidal vasculopathy (PCV) with hemorrhagic complications is at higher risk for breakthrough vitreous hemorrhage (VH). This study aimed to evaluate the clinical features and outcomes of breakthrough VH secondary to PCV. Data of patients receiving pars plana vitrectomy for breakthrough VH secondary to PCV (VH group) were evaluated retrospectively and compared statistically to data of age and sex-matched PCV patients without breakthrough VH (control group). Among PCV patients, 36 eyes with breakthrough VH and 62 eyes without VH were included. Compared with baseline, best corrected visual acuity (BCVA) was worse in the VH group (P < 0.001), and improved postoperatively (P < 0.001). Percentages of pigmented epithelial detachment (PED), hemorrhagic PED, massive subretinal hemorrhage, hemorrhagic retinal detachment (RD), and hemorrhagic choroidal detachment (CD) (P = 0.007) were higher in the VH group (P < 0.001). Incidence of choroidal vascular hyperpermeability (P < 0.001), massive subretinal hemorrhage (P = 0.001), hemorrhagic retinal detachment (P = 0.001) and hemorrhagic type PCV (P = 0.001) was higher in patients with pachychoroid PCV, while fibrovascular type had lower incidence (P < 0.001). Better initial BCVA (P < 0.001), higher frequency of anti-VEGF treatment (P = 0.009), and previous photodynamic therapy (P = 0.017) showed better visual outcomes. Breakthrough VH risk is higher in PCV patients with massive subretinal hemorrhage, hemorrhagic PED and hemorrhagic RD. BCVA and hemorrhagic complications improve significantly postoperatively. Higher frequency of anti-VEGF treatment and previous photodynamic therapy are associated with better visual prognosis in PCV patients with breakthrough VH.
Identifiants
pubmed: 36584198
doi: 10.1371/journal.pone.0279778
pii: PONE-D-22-26561
pmc: PMC9803236
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0279778Informations de copyright
Copyright: © 2022 Li, Tsen. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Ophthalmology. 2008 Jan;115(1):141-6
pubmed: 17582498
J Ocul Pharmacol Ther. 2010 Oct;26(5):469-74
pubmed: 20925578
Am J Ophthalmol. 1982 Dec;94(6):762-73
pubmed: 7180915
Acta Ophthalmol. 2016 Dec;94(8):e765-e771
pubmed: 27237048
Retina. 2018 Oct;38(10):1993-2000
pubmed: 28834950
Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):137-42
pubmed: 18766368
Arch Ophthalmol. 1991 May;109(5):723-9
pubmed: 2025175
Am J Ophthalmol. 2008 Oct;146(4):513-519
pubmed: 18614133
Acta Ophthalmol. 2010 Jun;88(4):e107-14
pubmed: 20337601
Am J Ophthalmol. 2013 Jan;155(1):96-102.e1
pubmed: 22995028
Ophthalmology. 1999 Oct;106(10):1900-6; discussion 1906-7
pubmed: 10519583
Surv Ophthalmol. 1987 Sep-Oct;32(2):123-30
pubmed: 3317954
Ophthalmologica. 1999;213(2):97-102
pubmed: 9885385
Retina. 2007 Mar;27(3):335-41
pubmed: 17460589
Retina. 2020 Jul;40(7):1403-1411
pubmed: 31181038
BMC Ophthalmol. 2020 Apr 15;20(1):150
pubmed: 32293353
Retina. 2011 Oct;31(9):1827-34
pubmed: 21734621
Sci Rep. 2018 Jul 12;8(1):10560
pubmed: 30002432
Am J Ophthalmol. 2012 Nov;154(5):872-880.e2
pubmed: 22831838
Retina. 2007 Mar;27(3):329-34
pubmed: 17460588
JAMA Ophthalmol. 2020 Sep 1;138(9):935-942
pubmed: 32672800
Retina. 1990;10(1):1-8
pubmed: 1693009
Retina. 1991;11(2):250-8
pubmed: 1925092
Am J Ophthalmol. 2000 Apr;129(4):546-7
pubmed: 10764874
Retina. 2013 Sep;33(8):1659-72
pubmed: 23751942
Retina. 1998;18(5):481-3
pubmed: 9801051
Eur J Ophthalmol. 2020 Nov;30(6):1473-1479
pubmed: 31476891
Arch Ophthalmol. 1996 Jun;114(6):693-7
pubmed: 8639080
Graefes Arch Clin Exp Ophthalmol. 2018 Dec;256(12):2309-2317
pubmed: 30259090
Surv Ophthalmol. 2004 Jan-Feb;49(1):25-37
pubmed: 14711438
Am J Ophthalmol. 2002 May;133(5):639-48
pubmed: 11992861
Retina. 2021 Aug 1;41(8):1675-1685
pubmed: 33395221
Ophthalmologica. 2004 May-Jun;218(3):193-201
pubmed: 15103216
Arch Ophthalmol. 2003 Jan;121(1):91-6
pubmed: 12523892
Retina. 2012 Sep;32(8):1453-64
pubmed: 22426346